SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Asus Zenbook S 14 embraces AI revolution with Intel's Core Ultra Processor

Hezbollah missiles threaten Adani's Haifa Port: What happens if Israel’s key trade hub shuts down?

TechnoPulm raises $2 million to develop a handheld device capable of performing full lung function tests

Bill Ackman sees 80% return on Tel Aviv Stock Exchange investment in just 10 months

Buzz

Most popular

Daily

Weekly

1

Intel employees brace for layoff notices as cuts to move into high gear next week

2

How Intel's $108 billion buyback gambit backfired—a cautionary tale for tech giants

3

"We’ll be looking out for you": Intel CEO Gelsinger stands with Israeli team

4

Bill Ackman sees 80% return on Tel Aviv Stock Exchange investment in just 10 months

5

OpenWeb turmoil: Jeff Horing's role in ousting CEO Nadav Shoval reveals the unicorn industry's dark underbelly

Gilead

6 stories about Gilead

מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman

The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies

פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy

Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights

ההכרזה של דולנד טראמפ על ירושלים 2

CTech’s Daily Israeli Tech News Roundup

Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich

With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich

The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales